Galil Medical gains $52M in VC

Thomas, McNerney and The Vertical Group have led a $52 million venture round for Israel's Galil Medical. Galil Medical develops and markets a cryotherapy platform that uses freezing technology and proprietary needle design for treating prostate and kidney cancer as well as other conditions. Galil has more than $20 million in annual revenue.

"We are now well positioned both organizationally and financially, to expand our global sales and marketing activities as well as to invest in R&D and clinical programs required to support existing and new applications for our cryotherapy technology," says CEO Chen Barir.

- read the release on the round

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.